Рэнди Эпштейн - Возбуждённые - таинственная история эндокринологии. Властные гормоны, которые контролируют всю нашу жизнь (и даже больше)

17. Hoberman, Testosterone Dreams , 120.

18. Metzger and Burnett, “Impact of Recent FDA Ruling.”

19. Shalender Bhasin et al., “Testosterone Therapy in Adult Men with Androgen Defi ciency Syndromes: An Endocrine Society Clinical Practice Guidline,” Journal of Clinical Endocrinology and Metabolism 95, no. 6 (2010): 2536–2559; Frederick Wu et al., “Identifi cation of Late-Onset Hypogonadism in Middle-Aged and Elderly Men,” New England Journal of Medicine 363, no. 2 (2010): 123–135; G. R. Dohle et al., “Guidelines on Male Hypogonadism,” European Association of Urology, 2014, http://uroweb.org/wp-content/uploads/18-Male-Hypogonadism_LR1.pdf.

20. Joseph Scott Gabrielsen et al., “Trends in Testosterone Prescription and Public Health Concerns,” Urologic Clinics of North America 43, no. 2 (2016): 261–271; Katherine Margo and Robert Winn, “Testosterone Treatments: Why, When, and How?” American Family Physician 73, no. 9 (2006): 1591–1598.

21. L. M. Schwartz and S. Woloshin, “Low ‘T’ as in ‘Template’: How to Sell Disease,” JAMA Internal Medicine 173, no. 15 (2013): 1460–1462.

22. W. J. Bremner et al., “Loss of Circadian Rhythmicity in Blood Testosterone Levels with Aging in Normal Men,” Journal of Clinical Endocrinology and Metabolism 56, no. 6 (1983): 1278–1281.

23. Fred Sattler et al., “Testosterone and Growth Hormone Improve Body Composition and Muscle Performance in Older Men,” Journal of Clinical Endocrinology and Metabolism 94, no. 6 (2009): 1991–2001.

24. Доктор Александр Пастушак, интервью автора.

25. A. M. Matsumoto, “Effects of Chronic Testosterone Administration in Normal Men: Safety and Effi cacy of High Dosage Testosterone and Parallel Dose-Dependent Suppression of Luteinizing Hormone, Follicle-Stimulating Hormone, and Sperm Production,” Journal of Clinical Endocrinology and Metabolism 70, no. 1 (1990): 282–287.

26. L. Frederiksen et al., “Testosterone Therapy Decreases Subcutaneous Fat and Adiponectin in Aging Men,” European Journal of Endocrinology 166 (2012): 469–476.

27. Shehzad Basaria et al., “Adverse Events Associated with Testosterone Administration,” New England Journal of Medicine 363, no. 2 (2010): 109–122; S. Basaria et al., “Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men with Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial,” Journal of the American Medical Association 314, no. 6 (2015): 570–581.

28. P. J. Snyder et al., “Effects of Testosterone Treatment in Older Men,” New England Journal of Medicine 374, no. 7 (2016): 611–624.

29. Felicitas Buena et al., “Sexual Function Does Not Change when Serum Testosterone Levels Are Pharmacologically Varied within the Normal Male Range,” Fertility and Sterility 59, no. 5 (1993): 1118–1123; Christina Wang et al., “Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men,” Journal of Clinical Endocrinology and Metabolism 85, no. 8 (2000): 2839–2853.

30. Доктор Шалендер Бхасин, интервью автора.

31. Darius Paduch et al., “Testosterone Replacement in Androgen-Defi cient Men With Ejaculatory Dysfunction: A Randomized Controlled Trial,” Journal of Clinical Endocrinology and Metabolism 100, no. 8 (2015): 2956–2962; Snyder et al., “Effects of Testosterone Treatment in Older Men.”

32. S. M. Resnick et al., “Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment,” Journal of the American Medical Association 317, no. 7 (2017): 717–727.

33. Partnership for the Accurate Testing of Hormones, “PATH Fact Sheet: The Importance of Accurate Hormone Tests,” Endocrine Society, Washington DC, 2017.

34. Доктор Мохит Кера, интервью автора. Mohit Khera et al., “Adult-Onset Hypogonadism,” Mayo Clinic Proceedings 91, no. 7 (2016): 908–926. Mohit Khera, “Male Hormones and Men’s Quality of Life,” Current Opinion in Urology 26, no. 2 (2016): 152–157.

35. Joel S. Finkelstein et al., “Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men,” New England Journal of Medicine 369, no. 11 (2013): 1011–1022.

36. Eder, “The Birth of Gender,” 83.

37. Natasha Singer, “Selling That New-Man Feeling,” New York Times , November 23, 2013; Sky Chadde, “How the Low T Industry Is Cashing in on Dubious, and Perhaps Dangerous, Science,” Dallas Observer , November 12, 2014; Sarah Varney, “Testosterone, The Biggest Men’s Health Craze Since Viagra, May Be Risky,” Shots: Health News from NPR , April 28, 2014, www.npr.org/sections/healthshots/2014/04/28/305658501/

prescription-testosterone-the-biggest-men-s-health-craze-since-viagra-may-be-ris.

38. Рона Шварцберг, советник по образованию Американской академии антивозрастной медицины, интервью автора. https://www.a4m.com/certification-in-metabolic-and-nutritional-medicine.html.

39. Weintraub, Selling the Fountain of Youth .

40. Adriane Fugh-Berman, “Should Family Physicians Screen for Testosterone Defi ciency in Men?” American Family Physician 91, no. 4 (2015): 227–228; J. J. Heidelbaugh, “Should Family Physicians Screen for Testosterone Defi ciency in Men? Yes: screening for testosterone defi ciency is worthwhile for most older men,” American Family Physician 91, no. 4 (2015): 220–221.

41. Arlene Weintraub, “What’s Next For The Thousands Of Angry Men Suing Over Testosterone?” Forbes online, April 6, 2015, http://www.forbes.com/sites/arleneweintraub/2015/04/06/whats-next-for-the-thousands-of-angry-men-suing-over-testosterone/-3915fbe04042; Arlene Weintraub, “AbbVie Challenges Fairness of Upcoming Testosterone Trials,” Forbes online, August 17, 2015, https://www.forbes.com/forbes/welcome/?toURL= https://www.forbes.com/sites/arleneweintraub/2015/08/17/abbvie-challenges-fairness-of-upcoming-testosterone-trials/&refURL= https://www.google.com/&referrer https://www.google.com/; Arlene Weintraub, “Testosterone Suits Soar Past 2,500 As Legal Milestone Looms For AbbVie,” Forbes online, October 30, 2015, http://www.forbes.com/sites/arleneweintraub/2015/10/30/testosterone-suits-soar-past-2500-as-legal-milestone-looms-for-abbvie/-229d1abc4b11; Arlene Weintraub, “Why All Those Testosterone Ads Constitute Disease Mongering,” Forbes online, March 24, 2015, http://www.forbes.com/sites/arleneweintraub/2015/03/24/why-all-those-testosterone-ads-constitute-disease-mongering/-711bf0463043.

42. Lisa Schencker, “AbbVie Must Pay $150 Million over Testosterone Drug, Jury Decides,” Chicago Tribune , July 24, 2017, http://www.chicagotribune.com/business/ct-abbvie-androgel-decision-0725-biz-20170724-story.html.

43. Доктор Питер Клопфер, интервью автора.

Эта глава написана на основе интервью с доктором Питером Клопфером, почетным профессором биологии Университета Дюка; доктором Кортом Педерсеном, профессором психиатрии и нейробиологии Университета Северной Каролины; и доктором Робертом Фромке, до центом нейробиологии Нью-Йоркского университета, в чьей лаборатории я побывала. Доктор Гидеон Нейв, до цент маркетинга Уортоновской школы Пенсильванского университета, помог мне разобраться со статистикой. Док тор Стив Чанг, доцент психологии и нейробиологии Йельского университета, рассказал мне о своей работе с обезьянами и окситоцином; доктор Дженнифер Барц, доцент психологии Университета Макгилла, говорила со мной о связи окситоцина и аутизма. Также я взяла интервью у доктора Майкла Платта, профессора антропологии Пенсильванского университета, и доктора Джеймса Хайэма, главного исследователя репродуктивной экологии и эволюции приматов Нью-Йоркского университета.